It becomes a global competition Discovering of coronavirus vaccine

In the three months since the virus began its deadly spread, China, Europe and the United States have all set off at a sprint to become the first to produce a vaccine.

And behind the scramble is a harsh reality: Any new vaccine that proves potent against the coronavirus — clinical trials are underway in the United States, China and Europe already — is sure to be in short supply as governments try to ensure that their own people are the first in line.

In China, 1,000 scientists are at work on a vaccine, and the issue has already been militarized: Researchers affiliated with the Academy of Military Medical Sciences have developed what is considered the nation’s front-runner candidate for success and is recruiting volunteers for clinical trials.

President Trump has talked in meetings with pharmaceutical executives about making sure a vaccine is produced on American soil, to assure the United States controls its supplies.

German government officials said they believed he tried to lure a German company, CureVac, to do its research and production, if it comes to that, in the United States.

Speaking in a teleconference on Thursday, executives from the five biggest pharmaceutical companies said they were working to increase the industry’s manufacturing abilities by sharing available capacity to ramp up production once a successful vaccine or antiviral is identified.ReadMore